<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALENDRONATE SODIUM</span><br/>(a-len'dro-nate)<br/><span class="topboxtradename">Fosamax, </span><span class="topboxtradename">Fosamax D (with 2800 IU Vitamin D3)<br/></span><b>Classifications:</b> <span class="classification">bisphosphonate</span>; <span class="classification">regulator, bone metabolism</span><br/><b>Prototype: </b>Etidronate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 35 mg, 40 mg, 70 mg tablets; 70 mg/75 mL oral solution</p>
<h1><a name="action">Actions</a></h1>
<p>Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption. Antiresorption mechanism is not fully understood.
         It does, however, localize preferentially to resorption sites of active bone turnover and has minimal to no interference with
         bone mineralization.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Alendronate decreases bone resorption thus minimizing loss of bone density.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention and treatment of osteoporosis in postmenopausal women, Paget's disease. Treatment of glucocorticoid-induced osteoporosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to alendronate or other bisphosphonates; severe renal impairment (Cl<sub>cr</sub> 35 mL/min); hypocalcemia; abnormalities; lactation, pregnancy (category C).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, CHF, hyperphosphatemia, liver disease, fever or infection, active upper GI problems.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Treatment of Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg once/d (max: 40 mg/d) or 70 mg q wk<br/><br/><span class="indicationtitle">Prevention of Osteoporosis, Treatment of Steroid-induced Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg q.d. or 35 mg q wk<br/><br/><span class="indicationtitle">Treatment of Paget's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg once/d for 6 mo<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Correct hypocalcemia before administering alendronate.</li>
<li>Administer in the morning at least 30 min before the first food, beverage, or medication. Do not administer within 2 h of
            calcium-containing foods, beverages, or medications. At least 30 min should elapse after alendronate dose before taking any
            other drugs.
         </li>
<li>
<i>Oral Solution:</i> Use oral syringe for accurate dosage. Give with at least 60 cc (2 oz) of plain water.
         </li>
<li>
<i>Tablet:</i> Give with 8 oz of plain water.
         </li>
<li>Keep patient sitting up or ambulating for 30 min after taking drug.</li>
<li>Store according to manufacturer's directions.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Endocrine:</span> Hypocalcemia, hypophosphatemia. <span class="typehead">GI:</span> Esophageal irritation and <span class="speceff-common">ulceration, nausea, vomiting, abdominal pain, dyspepsia,</span> diarrhea, constipation, flatulence. <span class="typehead">Other:</span> Arthralgias, myalgias, headache, rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Ranitidine</b> increases alendronate availability. <span class="typehead">Food:</span>
<b>Calcium</b> and food (especially dairy products) reduce alendronate absorption. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 0.51% absorbed from GI tract (absorption significantly decreased by calcium and food). <span class="typehead"> Onset:</span> 36 wk. <span class="typehead">Duration:</span> 12 wk after discontinuation. <span class="typehead">Distribution:</span> Rapid skeletal uptake. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Up to 50% excreted unchanged in urine. <span class="typehead">Half-Life:</span> Up to 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor albumin-adjusted serum calcium, serum phosphate, serum alkaline phosphatase, fasting and 24 h urinary calcium,
            and serum electrolytes. Periodically monitor renal and liver functions.
         </li>
<li>Diagnostic test: Bone density scan every 1218 mo.</li>
<li>Discontinue drug if the Cl<sub>cr</sub>
</li></ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Review directions for taking drug correctly (see <small>ADMINISTRATION</small>).
         </li>
<li>Report fever, especially when accompanied by arthralgia and myalgia.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>